Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVF-gel (Stromal Vascular Fraction gel) is an autologous, adipose-derived injectable product used for tissue regeneration and volume restoration. It is produced through the mechanical emulsification and centrifugation of lipoaspirate, which removes mature adipocytes while concentrating the stromal vascular fraction (SVF). This fraction is rich in adipose-derived stem cells (ADSCs), extracellular matrix (ECM) components, and various growth factors. Unlike traditional fat grafting, SVF-gel has a gel-like consistency that allows for precise injection through fine needles and promotes better survival and integration in the recipient site. In clinical settings, it is being investigated for conditions such as calcaneodynia (heel pain) associated with fat pad atrophy, where it aims to restore the cushioning properties of the heel and reduce inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SVF-gel.